Antipyretic and analgesic drugs are one of the most widely used drugs in the world and one of the major export categories of pharmaceutical raw materials in China. The export of antipyretic and analgesic APIs in China occupies a decisive position in the international market. In 2011, China's export volume of antipyretic and analgesic drugs fell by the same amount. The export volume was 108,800 tons, down 24.76% year-on-year; the export amount was 454 million US dollars, down 47.66% year-on-year; the average export price was 4.51 USD/kg. The year-on-year decrease was 30.43%.
The traditional market landscape is no longer in 2011. China's antipyretic and analgesic APIs are exported to 126 countries and regions. Asia, Europe, and North America are still the main markets for China's merchandise exports. The cumulative export volume accounted for 77.65% of the total.
Compared with 2010, China's exports of antipyretic analgesic drugs showed a significant downward trend in exports to the above three markets: the value of exports to Asia fell by 44.26%, of which, the value of exports to India decreased by 52.21%; the amount of exports to Europe and North America It decreased by 53.43% and 57% respectively, of which, the export value of the 15 EU countries fell by 58.86%; the value of the US exports decreased by 58.83%; and the decline of exports to emerging markets in Africa and Latin America also reached more than 30%. In 2011, the export of antipyretic and analgesic APIs in China was depressed.
Production enterprises play a major role in operations In 2011, a total of 610 enterprises engaged in the export of antipyretic and analgesic APIs decreased by 42.67% year-on-year. Judging from the top 20 companies in terms of export value, 17 enterprises are manufacturing enterprises, and the export value accounts for 74.53%; there are only 3 foreign trade companies and the export value accounts for 3.54%. This reflects that manufacturing companies have an operational advantage in this commodity export.
From the perspective of the export situation of domestic provinces, the export of antipyretic analgesics was mainly concentrated in the economically developed areas such as Shandong, Jiangsu and Zhejiang, and Shandong, Jiangsu, Zhejiang, Hebei, and Hubei ranked the top five in the export of antipyretic and analgesic APIs. Strong, the cumulative amount of exports in the five provinces accounted for as high as 87.99%, indicating that the concentration of anti-pyretic and analgesic export commodities in China is relatively high, and the development of industrial clusters is significant.
The four pillars have different market conditions, and the export market has been sluggish. The recovery of the market is still waiting for the day. Paracetamol is the most important export product of China's antipyretic and analgesic APIs. In 2011, the export volume accounted for 42.91% of the total. Affected by overcapacity and low price competition, acetaminophen has experienced a general decline in exports to major countries and regions. The amount of exports to Africa fell 26.46% year-on-year, of which exports to Nigeria fell 24.31% year-on-year; exports to Thailand and Vietnam, the main ASEAN countries, fell by 22.49% and 32.67% year-on-year, respectively; exports to emerging markets Brazil also fell sharply by 20%. the above. The downturn in the export of paracetamol directly dragged down the trend of the export market for antipyretic and analgesic APIs in 2011. In fact, in recent years, the export of paracetamol in China has been paralyzed in the shadow of disorderly competition and low-price competition. The industrial advantage has almost been lost. If the brand is not reshuffled, the recovery of performance will be difficult to achieve.
The main market advantage of ibuprofen is no longer, dragging down the export market for the whole year. In 2011, China’s ibuprofen exports to the major traditional markets declined significantly. Among them, the export value to the EU-15 countries fell by 9.44% year-on-year, and the export value to India decreased by 22.89% year-on-year. Affected by the European debt crisis and major competitors, such as the devaluation of the Indian currency, China's ibuprofen export prices have no obvious advantage in the major export markets, and corporate profits are further squeezed, directly affecting their future development.
The export volume of metamizole and aspirin increased steadily. The market leaders in Africa and Latin America were in stark contrast to the export conditions of paracetamol and ibuprofen. In 2011, exports of analgin and aspirin in China showed a good momentum of growth. Anianzhi's export value increased by 10.26% year-on-year, average export prices rose by 10.26% year-on-year, aspirin exports increased by 16.44% year-on-year, and average export prices rose by 7.31% year-on-year, both of which showed steady increases in prices. From the export market, emerging markets have become bright spots. Among them, the export value of Analgin to Africa increased by 25.17% compared with the same period of last year; the export amount to Latin America increased by 29.59%; the export amount of aspirin to Africa increased by 2.67%, and the export amount to Latin America increased by 76.25%. From the above statistics, it can be seen that the exports of Analgin and Aspirin have entered the period of strong demand. The reasons are inseparable from the strong demand in the mainstream market, the sound development of the Latin American economy, and the meticulous cultivation of my exporting companies in emerging markets.
Industrial restructuring is imminent In 2011, although there were bright spots in the export market for antipyretic and analgesic APIs, the overall situation was worrying. The major antipyretic and analgesic APIs in China are used for export, and their dependence on the international market is very high. Many manufacturing companies have old technology and low grades of products, making it difficult to enter the high-end market. In the absence of product advantages, companies can only compete for more market share by driving down prices, and competition is fierce. The tight market, tight supply, and rising prices have led to expansion of production capacity, oversupply, and price decline. This cycle has become a bottleneck for the development of the antipyretic and analgesic industry.
The reason is related to the irrational industrial structure of antipyretic analgesics in China. Over the years, the production scale of the antipyretic and analgesic industry in China has been continuously expanding. The output has doubled and the scale advantages have gradually emerged. However, the technological advantages and quality advantages have yet to be established. The expansion of the company's scale and output has not completely shaken off the mode of extensive growth. The new production line has blindly expanded production capacity, and progress in technology improvement and quality improvement is not obvious. Simply speaking about the scale of benefits without technical advantages, will inevitably affect the future development of the industry, resulting in a cyclical price war in the industry, and damaging China's antipyretic and analgesic pharmaceutical industry and the natural environment. Many years of disorderly market competition have made our country’s commodities’ ability to resist risks in the international market extremely weak.
Under this circumstance, China's antipyretic and analgesic API manufacturers have only to research and develop high-tech and high-quality products, eliminate production varieties that have entered recession, extend to high-end, specialty APIs, and improve product quality. Well-known brands can completely get out of the market downturn.
The traditional market landscape is no longer in 2011. China's antipyretic and analgesic APIs are exported to 126 countries and regions. Asia, Europe, and North America are still the main markets for China's merchandise exports. The cumulative export volume accounted for 77.65% of the total.
Compared with 2010, China's exports of antipyretic analgesic drugs showed a significant downward trend in exports to the above three markets: the value of exports to Asia fell by 44.26%, of which, the value of exports to India decreased by 52.21%; the amount of exports to Europe and North America It decreased by 53.43% and 57% respectively, of which, the export value of the 15 EU countries fell by 58.86%; the value of the US exports decreased by 58.83%; and the decline of exports to emerging markets in Africa and Latin America also reached more than 30%. In 2011, the export of antipyretic and analgesic APIs in China was depressed.
Production enterprises play a major role in operations In 2011, a total of 610 enterprises engaged in the export of antipyretic and analgesic APIs decreased by 42.67% year-on-year. Judging from the top 20 companies in terms of export value, 17 enterprises are manufacturing enterprises, and the export value accounts for 74.53%; there are only 3 foreign trade companies and the export value accounts for 3.54%. This reflects that manufacturing companies have an operational advantage in this commodity export.
From the perspective of the export situation of domestic provinces, the export of antipyretic analgesics was mainly concentrated in the economically developed areas such as Shandong, Jiangsu and Zhejiang, and Shandong, Jiangsu, Zhejiang, Hebei, and Hubei ranked the top five in the export of antipyretic and analgesic APIs. Strong, the cumulative amount of exports in the five provinces accounted for as high as 87.99%, indicating that the concentration of anti-pyretic and analgesic export commodities in China is relatively high, and the development of industrial clusters is significant.
The four pillars have different market conditions, and the export market has been sluggish. The recovery of the market is still waiting for the day. Paracetamol is the most important export product of China's antipyretic and analgesic APIs. In 2011, the export volume accounted for 42.91% of the total. Affected by overcapacity and low price competition, acetaminophen has experienced a general decline in exports to major countries and regions. The amount of exports to Africa fell 26.46% year-on-year, of which exports to Nigeria fell 24.31% year-on-year; exports to Thailand and Vietnam, the main ASEAN countries, fell by 22.49% and 32.67% year-on-year, respectively; exports to emerging markets Brazil also fell sharply by 20%. the above. The downturn in the export of paracetamol directly dragged down the trend of the export market for antipyretic and analgesic APIs in 2011. In fact, in recent years, the export of paracetamol in China has been paralyzed in the shadow of disorderly competition and low-price competition. The industrial advantage has almost been lost. If the brand is not reshuffled, the recovery of performance will be difficult to achieve.
The main market advantage of ibuprofen is no longer, dragging down the export market for the whole year. In 2011, China’s ibuprofen exports to the major traditional markets declined significantly. Among them, the export value to the EU-15 countries fell by 9.44% year-on-year, and the export value to India decreased by 22.89% year-on-year. Affected by the European debt crisis and major competitors, such as the devaluation of the Indian currency, China's ibuprofen export prices have no obvious advantage in the major export markets, and corporate profits are further squeezed, directly affecting their future development.
The export volume of metamizole and aspirin increased steadily. The market leaders in Africa and Latin America were in stark contrast to the export conditions of paracetamol and ibuprofen. In 2011, exports of analgin and aspirin in China showed a good momentum of growth. Anianzhi's export value increased by 10.26% year-on-year, average export prices rose by 10.26% year-on-year, aspirin exports increased by 16.44% year-on-year, and average export prices rose by 7.31% year-on-year, both of which showed steady increases in prices. From the export market, emerging markets have become bright spots. Among them, the export value of Analgin to Africa increased by 25.17% compared with the same period of last year; the export amount to Latin America increased by 29.59%; the export amount of aspirin to Africa increased by 2.67%, and the export amount to Latin America increased by 76.25%. From the above statistics, it can be seen that the exports of Analgin and Aspirin have entered the period of strong demand. The reasons are inseparable from the strong demand in the mainstream market, the sound development of the Latin American economy, and the meticulous cultivation of my exporting companies in emerging markets.
Industrial restructuring is imminent In 2011, although there were bright spots in the export market for antipyretic and analgesic APIs, the overall situation was worrying. The major antipyretic and analgesic APIs in China are used for export, and their dependence on the international market is very high. Many manufacturing companies have old technology and low grades of products, making it difficult to enter the high-end market. In the absence of product advantages, companies can only compete for more market share by driving down prices, and competition is fierce. The tight market, tight supply, and rising prices have led to expansion of production capacity, oversupply, and price decline. This cycle has become a bottleneck for the development of the antipyretic and analgesic industry.
The reason is related to the irrational industrial structure of antipyretic analgesics in China. Over the years, the production scale of the antipyretic and analgesic industry in China has been continuously expanding. The output has doubled and the scale advantages have gradually emerged. However, the technological advantages and quality advantages have yet to be established. The expansion of the company's scale and output has not completely shaken off the mode of extensive growth. The new production line has blindly expanded production capacity, and progress in technology improvement and quality improvement is not obvious. Simply speaking about the scale of benefits without technical advantages, will inevitably affect the future development of the industry, resulting in a cyclical price war in the industry, and damaging China's antipyretic and analgesic pharmaceutical industry and the natural environment. Many years of disorderly market competition have made our country’s commodities’ ability to resist risks in the international market extremely weak.
Under this circumstance, China's antipyretic and analgesic API manufacturers have only to research and develop high-tech and high-quality products, eliminate production varieties that have entered recession, extend to high-end, specialty APIs, and improve product quality. Well-known brands can completely get out of the market downturn.
Denture Box Serries,Denture Storage,Denture Storage Case,Denture Cases Boxes
Ningbo Carest Medical Instrument Co.,ltd , https://www.carestmed.com